Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
about
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesThe IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesisENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyInhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.HDACs and HDAC Inhibitors in Cancer Development and Therapy.A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.Targeting BTK through microRNA in chronic lymphocytic leukemia.[The IgH 3'RR: Doctor Jekyll and Mister Hyde of B-cell maturation and lymphomagenesis].Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplan
P2860
Q26771165-178BD5EC-82EE-4BEB-9D62-86794C446259Q26771812-7030B5C4-314D-4321-A5CC-3C5D5D8668CFQ28075599-F64826E0-1840-4CEC-9ADC-E0C826AEC348Q33432027-D3F29C9E-5025-4232-8B37-92A756AC8E41Q33437309-2C92E12B-F56D-4113-BD83-A53B44808DD4Q33438732-5E3DEEC6-8C95-42BF-80A4-CEA8A802BC8AQ33439519-D368324C-3F44-4136-B203-C8CAC596D613Q38595978-53D0A842-AD18-4CEC-B253-8DFF603E1953Q38947405-DBE2F1E3-5B71-44B7-BA00-F62548F26DD2Q40690632-FDAD58D6-7271-414C-B9A6-128BF624DDD6Q48967836-08B25ABC-C862-44A3-A0F7-0ADAA0C6A40BQ50098086-3A6143A9-876D-46F2-9A7F-056CF4788766Q52985786-2417271C-98BF-4C79-A1C5-CE10B5F3A57A
P2860
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@ast
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@en
type
label
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@ast
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@en
prefLabel
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@ast
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@en
P2093
P2860
P1476
Phase 1 study of the oral hist ...... chronic lymphocytic leukaemia.
@en
P2093
Andrea Varga
Anne-Laure Sarry
Bertrand Coiffier
Franck Morschhauser
Hélène Lelièvre
Ioana Kloos
Stéphane Depil
Vincent Ribrag
P2860
P2888
P304
P356
10.1007/S10637-015-0206-X
P577
2015-01-21T00:00:00Z
P6179
1043827289